Expression of interest: CBRN medical countermeasures R&D

A funding opportunity to develop and test medical countermeasures (vaccines, therapeutics, diagnostics, devices and other interventions) for chemical, biological, radiological and nuclear (CBRN) threats across the developmental pathway up to early-phase clinical studies (phase 2a). Projects must demonstrate how the research will improve domestic preparedness for CBRN incidents. Funding supports project costs including salaries, consumables, equipment, travel and dissemination.

Up to £4 million FEC per project with MRC funding 80% of costs; support for salaries, research staff, consumables, equipment, travel, data preservation/sharing, estates and dissemination and public partnership activities. Project duration up to 30 months.

Eligible applicants must be employed by a UK-based eligible research organisation and must direct and be actively engaged in the work; organisations confirm contractual arrangements for applicants without existing contracts. Project leads must be based at UK eligible research organisations. International research or commercial organisations are not eligible to lead or co-lead.

Submit a mandatory expression of interest (EOI) via the provided EOI survey; invited applicants may submit a full application through the UKRI funding service. Organisations apply; individuals may be project lead on only one application.